No Image 01Jun

by

Genosco gears up for IPO

No Image 01Jun

by

Oscotec`s acute leukemia treatment wins orphan drug status from FDA

No Image 01Jun

by

Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

No Image 01Jun

by

Yuhan ups investment in biotechs for immuno-oncology drug push

No Image 01Jun

by

"ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

No Image 01Jun

by

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

No Image 01Jun

by

More than half of Korean biopharma firms view R&D investments as assets.

No Image 01Jun

by

Oscotec shares rebound on launch of US clinical trial

No Image 01Jun

by

INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

No Image 01Jun

by

Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

No Image 01Jun

by

G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

No Image 01Jun

by

Profiles of Four New Stock-Billionaires